Medications That Cause Tinnitus (Ringing in the Ears)
Multiple drug classes are well-established causes of tinnitus, with chemotherapeutic agents (particularly cisplatin and carboplatin), aminoglycoside antibiotics, loop diuretics, and NSAIDs being the most common and potent offenders. 1, 2
Highest-Risk Medications
Chemotherapeutic Agents (Greatest Risk)
- Cisplatin increases tinnitus risk by 5.53-fold compared to non-ototoxic medications, making it the most potent ototoxic agent for causing tinnitus 1
- Carboplatin increases tinnitus risk by 3.75-fold, representing the second-highest risk among chemotherapy agents 1
- No treatment exists to reverse established ototoxicity from platinum-based chemotherapy 3
Antibiotics
- Aminoglycoside antibiotics (streptomycin, amikacin, kanamycin) cause both tinnitus and permanent hearing loss through destruction of auditory sensory cells in the organ of Corti 4, 2, 5
- Capreomycin causes tinnitus and deafness, particularly in elderly patients or those with preexisting renal impairment 4
- Ciprofloxacin shows strong association with tinnitus (ROR 9.96) in post-marketing surveillance data 6
- Chloramphenicol has minimal direct ototoxicity but potentiates noise-induced cochlear damage 7
Loop Diuretics
- Furosemide, bumetanide, and other loop diuretics cause acute, typically transient tinnitus and hearing impairment, especially with high-dose therapy 2, 5
- Thiazide diuretics (hydrochlorothiazide, indapamide) also cause tinnitus 4, 2
Anti-Inflammatory Medications
- NSAIDs (ibuprofen, naproxen, indomethacin, celecoxib, diclofenac) cause acute and typically transient tinnitus, particularly with high-dose therapy 2, 5
Moderate-Risk Medications
Cardiovascular Drugs
- Antiarrhythmics: amiodarone and dronedarone 4
- ACE inhibitors: ramipril, enalapril, quinapril 4
- Angiotensin receptor blockers: candesartan, irbesartan, losartan, olmesartan, telmisartan, valsartan 4
- Calcium channel blockers: amlodipine, diltiazem, nifedipine 4
- Statins: atorvastatin, pravastatin, simvastatin 4
Psychiatric Medications
- Antidepressants show strong association with tinnitus, particularly duloxetine (ROR 11.99, the highest among all drugs analyzed) 6
- Other antidepressants: citalopram, escitalopram, fluoxetine, paroxetine, sertraline, venlafaxine 4
- Antipsychotics: aripiprazole, chlorpromazine, clozapine, haloperidol, olanzapine, risperidone 4
- Anxiolytics: alprazolam, chlordiazepoxide 4
Other Antimicrobials
- Antifungals, antimalarials, anti-tuberculous drugs, antiretrovirals, beta-lactams, fluoroquinolones, sulfonamides, tetracyclines 4, 2
Critical Clinical Considerations
Risk Factors for Permanent Damage
- Renal insufficiency dramatically increases both ototoxicity and nephrotoxicity risk with aminoglycosides and capreomycin, requiring dose reduction to 2-3 times weekly (but maintaining mg/kg dose) 4
- Elderly patients face higher risk of vestibular disturbances, tinnitus, and deafness from capreomycin 4
- Pregnancy: capreomycin causes fetal nephrotoxicity and congenital hearing loss and should be avoided 4
Mechanism Patterns
- Drugs causing permanent hearing loss produce tinnitus secondary to cochlear damage (aminoglycosides, platinum chemotherapy, long-term antineoplastics) 2, 5, 7
- Drugs causing tinnitus without hearing loss likely act through central nervous system biogenic amine effects or proconvulsant mechanisms 7
- Pre-existing cochlear impairment is the underlying factor in most patients who develop drug-induced tinnitus 7
Synergistic Toxicity
- Simultaneous administration of multiple ototoxic agents causes synergistic hearing loss 5
- Noise exposure potentiates ototoxicity from cochleotoxic drugs, placing patients at greater risk than either exposure alone 5, 7
Management Approach
When Tinnitus Develops During Treatment
- For chemotherapy-induced tinnitus, hearing aids and cognitive behavioral therapy remain beneficial, though no treatment reverses established ototoxicity 3, 8
- Discontinuation may be necessary to prevent permanent damage when tinnitus develops with reversible ototoxic agents 2
- Monitor renal function, serum drug concentrations, and auditory function before and during therapy with high-risk medications 4, 2